An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Evidence review for post-surgical maintenance of remission: Crohn's disease: management: Evidence review.
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 129.)
Top results in this bookTable of Contents
Systematic review of treatments for atopic eczema.
Hoare C, Li Wan Po A, Williams H.
Southampton (UK): NIHR Journals Library; 2000 Dec. (Health Technology Assessment, No. 04.37.)
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
Evidence reviews for induction of remission in mild-to-moderate ulcerative colitis: Ulcerative colitis: management: Evidence review.
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 130.)
Drugs and Lactation Database (LactMed®) [Internet].
Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
Scoping systematic review of treatments for eczema.
Nankervis H, Thomas KS, Delamere FM, et al.
Southampton (UK): NIHR Journals Library; 2016 May. (Programme Grants for Applied Research, No. 4.7.)
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Ruxolitinib (Opzelura): Therapeutic area: Atopic dermatitis: Reimbursement Review [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2025 Sep.
Roflumilast (Zoryve): CADTH Reimbursement Review: Therapeutic area: Plaque psoriasis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Environmental Medicine: Integrating a Missing Element into Medical Education.
Institute of Medicine (US) Committee on Curriculum Development in Environmental Medicine; Pope AM, Rall DP, editors.
Washington (DC): National Academies Press (US); 1995.
Abrocitinib (Cibinqo): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis, moderate to severe [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Pharmacoeconomic Report: Dupilumab (Dupixent): (Sanofi Genzyme, a division of sanofi-aventis Canada Inc.): Indication: Indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jun.
Pharmacoeconomic Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul.
GeneReviews® [Internet].
Adam MP, Bick S, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2026.
Utilization of Old- Versus New-Generation Biologics for Plaque Psoriasis for Public and Private Payers in Canada: Technology Review [Internet].
Dyrda P, Vannabouathong C, Peter K, et al.; Authors.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.
Upadacitinib (Rinvoq): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Dupilumab (Dupixent): CADTH Reimbursement Review: Therapeutic area: Atopic dermatitis, pediatrics [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Dec.
Pharmacoeconomic Report: Halobetasol Propionate and Tazarotene (Duobrii): (Bausch Health, Canada Inc.): Indication: Psoriasis, moderate-to-severe plaque [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec.
Pharmacoeconomic Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited): Indication: Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on